PGR and neoplasm: MAI, PR status, and grade were significantly different between the groups: In the ultralow-risk group, 13% (3/23) of the patients had a tumor with MAI ≥ 8/2 mm2, while this was 35% (20/57) and 70% (37/53) for the genomic low and high-risk group, respectively.